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Abstract
Background: The insulinoma associated protein tyrosine phosphatase 2 (IA-2) is one of the immunodominant
autoantigens involved in the autoimmune attack to the beta-cell in Type 1 Diabetes Mellitus. In this work we have
developed a complete and original process for the production and recovery of the properly folded intracellular
domain of IA-2 fused to thioredoxin (TrxIA-2ic) in Escherichia coli GI698 and GI724 strains. We have also carried out
the biochemical and immunochemical characterization of TrxIA-2icand design variants of non-radiometric
immunoassays for the efficient detection of IA-2 autoantibodies (IA-2A).
Results: The main findings can be summarized in the following statements: i) TrxIA-2ic expression after 3 h of
induction on GI724 strain yielded ≈ 10 mg of highly pure TrxIA-2ic/L of culture medium by a single step purification
by affinity chromatography, ii) the molecular weight of TrxIA-2ic (55,358 Da) could be estimated by SDS-PAGE, size
exclusion chromatography and mass spectrometry, iii) TrxIA-2ic was properly identified by western blot and mass
spectrometric analysis of proteolytic digestions (63.25 % total coverage), iv) excellent immunochemical behavior of
properly folded full TrxIA-2ic was legitimized by inhibition or displacement of [
35S]IA-2 binding from IA-2A present
in Argentinian Type 1 Diabetic patients, v) great stability over time was found under proper storage conditions and
vi) low cost and environmentally harmless ELISA methods for IA-2A assessment were developed, with colorimetric
or chemiluminescent detection.
Conclusions: E. coli GI724 strain emerged as a handy source of recombinant IA-2ic, achieving high levels of
expression as a thioredoxin fusion protein, adequately validated and applicable to the development of innovative
and cost-effective immunoassays for IA-2A detection in most laboratories.
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Background
The insulinoma associated protein tyrosine phosphatase
2 (IA-2) is a 106 kDa (979 residues) transmembrane
glycoprotein [1–3] whose encoding gene is localized in
human chromosome 2q35. IA-2 is expressed in neuro-
endocrine cells, such as the peptidergic neurons of the
central nervous system, the chromaffin cells present in
the adrenal medulla and the endocrine pancreas (alpha
and beta-cells of the pancreatic islet) [3–5]. IA-2 belongs
to the protein tyrosine phosphatase (PTP) family, par-
ticularly to the receptor type PTPs; however, it lacks
such enzymatic activity [6, 7]. In pancreatic islets, IA-2
participates in the cytoplasmic transport of dense core
secretory granules (DSG) containing insulin, its subse-
quent excretion into the extracellular space, biogenesis,
storage and recycling, as well as in beta-cell proliferation
[8–12]. The IA-2 structure consists of three domains:
the extracellular domain (residues 1–576, which are in
contact with the DSG lumen during storage) that is sep-
arated from the intracellular domain or IA-2ic (residues
601–979, oriented to the beta-cell cytoplasm) by a single
transmembrane domain (residues 577–600). It was
demonstrated that, after exocytosis, calpain mediates
the release of IA-2ic from the plasma membrane; a
process after which IA-2 travels to the nucleus where
its inactive PTP domain binds to the phosphorylated
tyrosine present in the STAT5 protein, thus upregu-
lating gene expression of DSG proteins, including in-
sulin and IA-2 [13–16].
Diabetes Mellitus (DM) is a group of metabolic dis-
eases of heterogeneous etiology characterized by poor
metabolic control of patients and the presence of
marked hyperglycemia, which stems from defects in in-
sulin secretion and/or action [17]. According to the
American Diabetes Association, DM can be classified
into four main groups: Type 1, Type 2, gestational and
other types. Type 1 DM (T1DM) is characterized by the
destruction of pancreatic beta-cells leading to a defi-
ciency in insulin secretion that results in elevated blood
glucose levels [18–20]. The loss of tolerance to pancre-
atic islet antigens is known to be mediated by a T cell-
dependent autoimmune process. IA-2 is one of the
immunodominant autoantigens involved in the auto-
immune attack on the beta-cell in DM. The other
autoantigens implicated are: insulin, glutamic acid de-
carboxylase (GAD) and Zinc transporter 8 (ZnT8). The
autoantibodies specific to insulin, GAD, IA-2 and ZnT8
(IAA, GADA, IA-2A and ZnT8A, respectively) can be
detected in patient sera as the first detectable sign of
emerging beta-cell autoimmunity [21–23]. These auto-
antibodies are currently used as additional serological
markers to confirm the autoimmune process underlying
insulin deficiency in diabetic patients. These markers are
useful for predicting T1DM in children and to achieve
the correct diagnosis in adult patients with intermediate
forms of DM, like Latent Autoimmune Diabetes of the
Adults (LADA) [24–26].
IA-2A mostly recognize the IA-2ic (essentially the PTP
sequence, residues 696–979), since this domain is the
one exposed upon cell damage. IA-2A bind to discon-
tinuous epitopes, therefore, the correct folding of IA-2ic
is critical for immune recognition [27–30]. Moreover,
the diagnostic sensitivity in both newly diagnosed type 1
diabetic patients and pre-diabetic individuals is highest
when IA-2ic is used as antigen for IA-2A recognition,
thus suggesting that this domain should be used as de-
tection antigen in T1DM–related autoantibody screen-
ing studies [31, 32]. Approximately, 60–80 % of patients
with T1DM are positive for IA-2A [33, 34]. The prob-
ability of T1DM patients’ first-degree relatives contract-
ing DM within 5 years from the detection of the positive
marker is 65–85 % for IA-2A (positive predictive value),
since these autoantibodies are known to appear later
during the development of the autoimmune process.
Therefore, the detection of IA-2A can be considered in-
dicative of rapid disease progression [35, 36].
The assessment of a complete set of autoantibodies is
not only applied to confirm the existence of an under-
lying autoimmune process in infant-juvenile or adult
diabetic patients (clinical classification of DM), and to
monitor first-degree relatives of diabetic individuals
(population at risk), but also to predict the need for in-
sulin treatment. Besides, the presence of autoantibodies
can be used as inclusion criteria for enrolment in predic-
tion and prevention trials and as an endpoint in observa-
tional studies [31, 37–40]. The usefulness of IA-2A
detection lies in its high diagnostic specificity, since the
frequency of such a marker in healthy individuals is only
2–4 % [31, 41, 42]. The reference method for detection
of IA-2A is the Radioligand Binding Assay (RBA) [43],
which includes a recombinant radiolabelled autoantigen
as tracer for immunocomplex formation in a fluid phase.
This tracer is usually synthesized in cell-free eukaryotic
systems, bearing [35S]-marked aminoacids, making it en-
vironmentally inappropriate, expensive and limited to
authorized laboratories. The development of more ac-
curate, sensitive and inexpensive methods to detect IA-
2A can be helpful to achieve an early diagnosis or pre-
diction of DM. For these reasons, a handy source of
properly folded recombinant antigen is needed for the
development of innovative and cost-effective non-
radiometric immunoassays for the quasi-quantitative as-
sessment of IA-2A (such as solid phase ELISA-type as-
says) that are applicable to low or medium complexity
laboratories [44].
The most widespread recombinant expression system
is the prokaryotic one employing Escherichia coli. This
system has proved to be easy to handle, it is inexpensive
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and the protein expression yield is high [45, 46]. Differ-
ent fusion partners are often used to facilitate solubilisa-
tion and/or purification of eukaryotic proteins in this
system, such as the glutathione-S-transferase, the man-
nose binding protein or thioredoxin (Trx) [47–49]. We
have previously described the expression of IA-2 in E.
coli; however, the recombinant protein obtained was not
stable enough to be implemented in the routine diagno-
sis of autoimmune DM [50]. In this work we have devel-
oped a complete and original process for the production
and recovery of the properly folded intracellular domain
of IA-2 fused to Trx (TrxIA-2ic) in a prokaryotic ex-
pression system with high performance. We have also
carried out the biochemical and immunochemical
characterization of TrxIA-2ic and design variants of
non-radiometric immunoassays for the efficient detec-




Argentinian healthy control individuals
Control sera (n = 115, mean age of 29.7 years with me-
dian age of 25, range 16 to 80 and male/female: 58/57)
were obtained from Argentinian healthy individuals
without personal or family history of DM or auto-
immune diseases. The sample collection was approved
by the Ethics Committee of the José de San Martín
Clinical Hospital, University of Buenos Aires (UBA),
Buenos Aires, Argentina. All subjects were informed
about the purpose of the study, and a signed consent for
study participation was obtained. Autoantibodies assess-
ment was performed and all of the individuals were
negative. Sera were stored at -20 °C until assayed.
Argentinian Type 1 diabetic patients
Serum samples (n = 60, mean age of 9.2 years with me-
dian age of 9, range 2 to 21 and male/female: 23/37)
were collected from Argentinian children and adoles-
cents admitted to the Nutrition Service at Gutiérrez
National Pediatric Hospital, Buenos Aires, Argentina,
from May 2013 to March 2015. Samples from patients
fasted overnight (ON) were taken before or within 72 h
of starting insulin treatment. T1DM was diagnosed ac-
cording to WHO criteria [51]. Sample collection and
protocols were approved by the Ethics Committees of the
Gutiérrez National Pediatric Hospital. Parental consent
was obtained. Sera were stored at -20 °C until assayed.
Rabbit policlonal sera against IA-2
Recombinant IA-2ic fused to a C-terminal His-tag
(IA-2icHis6) was obtained as previously described by
Sica et al [50]. IA-2 antibodies were obtained through
immunization of New Zealand white rabbits (n = 3)
with 0.1 mg of IA-2icHis6 emulsified in complete
Freund’s adjuvant. The initial injection was followed
by booster injections with 0.1 mg of IA-2icHis6 in in-
complete Freund’s adjuvant at three-week intervals.
Rabbits were bled 15 days after the booster dose.
Rabbit polyclonal sera against thioredoxin
Recombinant Trx was expressed in E. coli with the pTrx
vector (Invitrogen, Carlsbad, CA, USA) and purified by
osmotic shock according to the manufacturer’s instruc-
tions. The product was dialyzed against phosphate-
buffered saline (PBS, 1.5 mM KH2PO4, 8.1 mM
Na2HPO4, 0.14 M NaCl, 2.7 mM KCl, and pH 7.4) and
lyophilized. The antiserum against Trx was obtained by
immunizing New Zealand white rabbits (n = 3) with
1.0 mg of recombinant Trx emulsified in complete
Freund’s adjuvant. The initial injection was followed by
booster injections with 1.0 mg of Trx in incomplete
Freund’s adjuvant at four-week intervals. Rabbits were
bled 15 days after boosting. All animals were housed
under specific conditions according to the “Guide for
the Care and Use of Laboratory Animals” by the
National Research Council of the National Academies
(USA); experiments were performed in compliance with
the Argentinian animal protection laws and approved by
the “Prof. Ricardo A. Margni” Humoral Immunity
Studies Institute (IDEHU), National Research Council
(CONICET-UBA).
IA-2ic expression as a fusion protein with thioredoxin in
E. coli
Expression vector and E. coli transformation
Unless otherwise indicated, standard molecular-biology
protocols were used [52]. The coding sequence of
human IA-2ic (residues 604 to 979) was adapted from
the sequences found in NCBI GenBank (L18983.1:
Homo sapiens tyrosine phosphatase (IA-2/PTP) mRNA,
complete cds). Human IA-2ic codons were customized
to those used with the highest frequencies in E. coli
(codon optimization). The IA-2ic optimized nucleotide
sequence was synthesized by Genscript (GenScript
Corporation, Piscataway, NJ, USA; www.GenScript.com),
including SmaI and XbaI restriction sites at the 3’ and 5’
ends, respectively. The synthesized construct (1128 bp)
was obtained from Genscript in plasmid pUC57 and
maintained in JM109 E. coli (Promega, Madison, WI,
USA). After vector propagation and purification with
QIAprep spin Miniprep Kit (QIAGEN, Hilden, Germany),
the IA-2ic construct was released with SmaI and XbaI and
ligated to the pTrxFus linearized vector (Invitrogen,
Carlsbad, CA, USA) to yield pTrxIA-2ic (Fig. 1). The
quality of the new vector encoding the fusion protein
TrxIA-2ic was corroborated by sequencing (Macrogen Inc,
Seoul, Korea). Competent E. coli GI698 (Invitrogen,
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Carlsbad, CA, USA) and GI724 (ATCC® 55151™) strains
were transformed with pTrxIA-2ic by electroporation.
Protein expression and E. coli disruption
Bacteria were cultured at 30 °C in 0.2 % w/v casein
amino acids, 0.5 % w/v glucose, 1 mM MgCl2, and
100 μg/mL ampicillin, and protein expression was in-
duced with 100 μg/mL tryptophan at 20 °C for GI698 or
37 °C for GI724. Different timepoints during the course
of the induction period were collected; including 1.5, 3.0
and 16.0 h. Before and after the induction of protein ex-
pression, bacterial pellets from 1 mL culture were col-
lected by centrifugation, suspended in 0.2 mL of SDS-
PAGE sample buffer (50 mM Tris-HCI, 12 % w/v gly-
cerol, 0.005 % w/v bromophenol blue, 4 % w/v SDS,
4 % v/v 2-mercaptoethanol -2ME-, pH 6.8) and boiled
for 5 min to obtain the total cell lysate (TCL). A bacterial
pellet was collected from 200 mL culture by centrifuga-
tion, suspended in 2 mL lysis buffer (50 mM Tris-HCl,
100 mM NaCl, 1 mM EDTA, pH 7.0) and sonicated in the
presence of 1 mM 2ME and protease inhibitors (0.1 % w/v
aprotinin and 2 mM phenylmethylsulfonyl fluoride) over
crushed ice. After sonication, Triton X-100 was added to a
final concentration of 0.1 % v/v and incubated for 10 min
at 0 °C. The intracellular soluble fraction (ISF) was then
separated by centrifugation at 15,000 rpm for 10 min at
4 °C.
Purification by affinity chromatography
TrxIA-2ic was purified by means of affinity chromatog-
raphy following the protocol previously described [53].
The resin was based on an agarose support covalently
modified with phenylarsine oxide (Additional file 1:
Figure S1), which permitted the binding of proteins con-
taining vicinal dithiol residues, as in Trx [54]. This resin,
previously equilibrated in lysis buffer (≈4 mL) and acti-
vated with four column volumes (CV) of lysis buffer
containing 20 mM 2ME, was added to the lysate (4 mL),
and the resulting suspension was incubated for 1.5 h at
4 °C. The resin was poured into a column (0.7 cm ×
9.0 cm) and washed sequentially with six CV lysis buffer,
six CV lysis buffer containing 1 mM 2ME and three CV
lysis buffer containing 5 mM 2ME. Bound proteins were
eluted with several 2 mL of the lysis buffer containing
100 mM 2ME. The protein concentration in purified
fractions was determined using the Coomasie Plus
(Bradford) Assay kit (ThermoScientific, Rockford, IL,
USA). Aprotinin was added to a final concentration of
0.1 % w/v.
Biotinylation of TrxIA-2ic
Two mL of the purified fusion protein were subjected to
buffer exchange to PBS using a ZEBA desalt spin col-
umn (Pierce Biotechnology, Rockford, IL, USA) accord-
ing to the manufacturer’s instructions. The desalted
protein was then incubated for 2 h at 0 °C with a 20-fold
molar excess of sulfo-NHS-biotin (Pierce Biotechnology,
Rockford, IL, USA). Free biotin was removed on a new
ZEBA desalt spin column. Higher biotinylation rates
were also tested with a 435-fold excess of sulfo-NHS-
biotin.
Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis and western blot analysis
TCL and ISF were analyzed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
under reducing conditions, followed by Coomasie
Brilliant Blue R-250 staining [55], and western blot (WB)
[56]. For comparison, all SDS-PAGE lanes in each gel
contained proteins recovered from the same amount of
cells. Protein bands were transferred to nitrocellulose
membranes and unoccupied binding sites were blocked
by incubating with 3 % w/v skim milk in Tris buffer sa-
line (TBS; 0.05 M Tris-HCl, 0.15 M NaCl, pH 7.5) for
2 h at room temperature (RT). After 3 washing steps
with 0.05 % v/v Tween 20 in TBS (TBS-T) membranes
were incubated ON at RT with polyclonal sera to Trx or
Fig. 1 Map of the vector constructed for the expression of TrxIA-2ic
in E. coli. The pTrxFus vector was used to create a C-terminal fusion
to E. coli thioredoxin. The IA-2ic optimised sequence was inserted
into the multiple cloning site of the expression vector and expressed
as amino terminal fusion to the E. coli protein thioredoxin. This vector
includes an enterokinase (EK) cleavage site that allows release of the
native protein from Trx. To drive expression of thioredoxin fusions,
pTrxFus uses the pL promoter from the λ bacteriophage and the AspA
transcription terminator. Plasmid selection and maintenance is ensured
by the presence of a beta-lactamase gene (BLA) that provides
ampicillin resistance. SmaI and XbaI sites are indicated at the 3’
and 5’ ends of the IA-2ic sequence. RBS: ribosome binding site
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IA-2 diluted 1/100 in 3 % w/v skim milk, 0.05 % v/v
Tween 20 in TBS (TBS-MT), and then washed five times
with TBS-T. Bound antibodies were visualized by incu-
bation with peroxidase-conjugated goat antibodies to
rabbit IgG (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA) diluted 1/2000 in TBS-MT, followed
by the addition of alpha-chloronaphthol (Sigma-Aldrich,
Inc., St Louis, MO) and 10 vol H2O2.
Biochemical characterization of TrxIA-2ic
Molecular weight determination by SDS-PAGE
The general SDS-PAGE procedure consisted in separat-
ing several conventional protein standards with known
molecular weight (MW) (Amersham Pharmacia Biotech,
Little Chalfont Buckinghamshire, England) in parallel
with a TrxIA-2ic sample in a 10 % T, 6 % C acrylamide
gel with 1.5 mm thickness and under reducing condi-
tions [55]. The standard proteins were used to generate
a curve correlating MW and migration in the gel
(relative mobility or Rf ), from which the MW of the
TrxIA-2ic sample was estimated.
Analytical size-exclusion chromatography
Size-Exclusion chromatography (SEC) was performed on
an FPLC ÄKTA system (GE Healthcare, Sweden)
equipped with a Superdex 75 HR 10/30 column
(Pharmacia Biotech, Uppsala, Sweden). The chromato-
graphic process was performed at RT with PBS as mo-
bile phase at a flow rate of 1.0 mL/min and the
absorbance was monitored at 280 nm. The MW, hydro-
dynamic dimension and aggregation state were assessed
[57]. SEC calibration curves were generated, employing
MW standard proteins (gel filtration standard, Bio-Rad,
Hercules, CA, USA), using linear regression analysis of
the plot of peak elution volume (Ve) vs. the logarithm of
their MW, obtained from chromatographic trace. In par-
allel, purified TrxIA-2ic (50 μg/500 μL) was injected and
the Ve obtained was interpolated in the calibration plot
in order to estimate MW and aggregation state of the
sample.
Mass spectrometry analysis
In order to assess total protein MW, affinity purified
TrxIA-2icwas subjected to mass spectrometry (MS) ana-
lysis. Briefly, a 1 μL aliquot of the sample was spotted
onto an AnchorChip (Bruker, Billerica, MA, USA).
One μL of an oversaturated solution of sinapinic acid
in 30/70/0.1 % v/v acetonitrile/water/TFA was added
to the sample and left to crystallize by air-drying.
Samples were analyzed on a Bruker Microflex MALDI-
TOF device (Bruker, Billerica, MA, USA). In order to fur-
ther characterize and identify the protein, TrxIA-2ic was
subjected to proteolytic digestion and MS analysis. Con-
cisely, the sample was dissolved in 50 mM NH4HCO3
buffer, pH 8; a volume equivalent to 20 μg was subjected
to disulfide bond reduction, with 20 mM dithiothreitol for
45 min at 56 °C, and alkylation with 20 mM iodoaceta-
mide for 45 min at RT in the dark. The sample was then
diluted to a final concentration of 1 M urea. Finally, tryp-
sin and chymotrypsin proteolytic digestion were per-
formed separately and samples were analyzed by
nanoHPLC (EASY-Spray Accucore, Thermo scientific,
West Palm Beach, FL, USA) coupled to a mass spectrom-
eter with Orbitrap technology (Q-Exactive, Thermo
Scientific, West Palm Beach, FL, USA; at Centro de
Estudios Químicos y Biológicos por Espectrometría de
Masa -CEQUIBIEM- CONICET-UBA, Argentina), enab-
ling both separation and identification of peptides.
Ionization of samples was made by electrospray (EASY-
SPRAY, Thermo Scientific, West Palm Beach, FL, USA)
and data analysis was performed by the Proteome
Discoverer software version 1.4, Thermo Scientific.
Coverage percentages were calculated based on the num-
ber of identified peptides/total number of peptides.
Immunochemical characterization of TrxIA-2ic
Synthesis of [35S]IA-2 tracer
The [35S]IA-2 tracer was obtained by in vitro
transcription/translation of the cDNA coding for human
IA-2iccloned into pSP64 vector (Promega, Madison, WI,
USA), using a rabbit reticulocyte lysate system (Promega,
Madison, WI, USA) in the presence of [35S]-methionine
(New England, Nuclear, Boston, MA, USA), according
to the manufacturer’s instructions. Translation prod-
ucts were diluted in radioimmunoassay (RIA) buffer
(0.02 M Tris-HCl, 0.15 M NaCl, 0.1 % v/v Tween 20,
pH 7.4) and applied to a PD10 column (Pharmacia-LKB
Biotechnology, Uppsala, Sweden) in order to remove free
[35S]-methionine. Typically, the percentage of incorpor-
ation of [35S]-methionine to the protein by this method
was 5–7 %, yielding about 5–7×106cpm of labelled pro-
tein. The tracer was stored in aliquots at -40 °C, and had a
shelf life of 5 weeks.
Radioimmunoassay protocol
Quantitative competition assays were performed by
standard Radioimmunoassay (RIA) protocols. The incu-
bation of 2.5 μL of IA-2A(+) Type 1 diabetic patient sera
with 10,000 cpm of [35S]IA-2 in the presence of serial
concentrations (90.0 pM – 0.6 μM in a final volume of
60 μL) of purified TrxIA-2ic from ISF was performed in
duplicate. After ON incubation, 50 μL of 40 % v/v pro-
tein A-Sepharose 4B FF (GE Healthcare Biosciences,
Uppsala, Sweden) in RIA buffer were added and incu-
bated for 2 h at RT on an end-over-end shaker. Subse-
quently, samples were allowed to settle and the
supernatants were discarded in order to isolate immuno-
complexes. Pellets were washed three times with 200 μL
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of RIA buffer and once with 200 μL of 0.2 M NaCl in
RIA buffer. Finally, pellets were suspended in 100 μL of
1 % w/v SDS and supernatants were carefully transferred
to vials for scintillation counting (1 min/tube). Results
for each sample were calculated as Bound% (B%) = 100 ×
(bound cpm/total cpm). Inhibitory Dose-response curves
[log (inhibitor) vs. response - Variable slope (four param-
eters)] were fitted to the mathematical function:
B=B0 ¼ B=B0minþ ðB=B0maxB=B0minÞ=
ð1þ 10½ðlog IC50log TrxIA2ic doseÞHill SlopeÞ
Where B corresponds to B% measurements, B0 is the
B% at zero concentration of unlabelled antigen, B/B0min
and B/B0max are the minimal and maximal response,
respectively and the parameter IC50 represents the con-
centration of TrxIA-2ic that gave a response half be-
tween B/B0min and B/B0max. Hill Slope describes the
steepness of the family of curves. The same protocol was
performed for TrxIA-2ic-biotin, in serial concentrations
of 12.0 pM – 0.7 μM.
Inhibition assay
The ability of TrxIA-2ic to compete with [
35S]IA-2 for
the binding to antibodies was assessed qualitatively by
incubating sera from 30 IA-2A(+) Type 1 diabetic pa-
tients with the tracer in the presence of TrxIA-2ic excess
(190 nM). Briefly, 2.5 μL of human sera were incubated
ON at 4 °C with 10,000 cpm of [35S]IA-2 in the absence
or presence of unlabelled TrxIA-2ic in a final volume of
60 μL in RIA buffer. Immunocomplexes were isolated
with protein A-Sepharose 4B FF; pellets were washed
and suspended in 1 % w/v SDS, as described in the RIA
protocol. The radioactivity of supernatants was counted.
Results for each sample (with or without TrxIA-2ic) were
calculated as B%, and expressed as Standard Deviation
scores (SDs) = (B% - Bc%) /SDc, where Bc% is the mean
B% of healthy control sera and SDc its standard devi-
ation. The same protocol was followed for TrxIA-2ic-
biotin in the presence of antigen excess (140 nM).
Storage and stability studies
Inhibition dose-response curves were performed over
time as previously described. Briefly, a 2.5 μL aliquot of
a pool of sera from 5 IA-2A (+) Type 1 diabetic patients
was incubated with the tracer [35S]IA-2 and several dilu-
tions of purified TrxIA-2ic in two different storage con-
ditions. These conditions included TrxIA-2ic stored at
-20 °C with or without the addition of glycerol to a final
concentration of 50 % v/v in lysis buffer either with
100 mM 2ME or 50 mM 2ME, respectively. The study
was performed over the course of 120 days and dose-
response curves of log [TrxIA-2ic] vs. B/B0 were ana-
lyzed at each time for both conditions. The parameter
IC50 was selected for comparison and selection of the
optimal storage condition.
TrxIA-2ic application in immunoassays for IA-2A
assessment
Reagents
PBS was used as the microplate coating buffer. Two
percent w/v skim milk in PBS (PBS-M) and PBS con-
taining 0.05 % v/v Tween 20 (PBS-T) were used as
blocking solution and washing buffer, respectively. Sam-
ple or reagent dilutions were prepared in 2 % w/v skim
milk, 0.05 % v/v Tween 20 in PBS (PBS-MT). Immuno-
pure Avidin was purchased from Pierce, and Avidin–
Horseradish Peroxidase (HRP) and rabbit anti-human
IgG-HRP were purchased from Jackson ImmunoResearch
Laboratories, Inc. The 3,3’,5,5’-tetramethyl-benzidine/
H2O2 (Single Component TMB Peroxidase EIA Substrate
Kit, BioRad, Hercules, CA, USA) was employed as the
chromogenic substrate and the SuperSignal ELISA Pico
(ThermoScientific, Rockford, IL, USA) as the chemilumin-
escent substrate. Except when otherwise indicated, incu-
bations were performed at RT, washing steps were
performed with PBS-T and 50 μL per well were added in
each incubation step.
Radioligand binding assay (RBA) protocol
RBA was performed as previously described [43] with
minor modifications [50, 58]. Briefly, 2.5 μL of human
sera were incubated ON at 4 °C with 10,000 cpm of
[35S]IA-2 in a final volume of 60 μL in RIA buffer. After
that, 50 μL of 40 % v/v protein A-Sepharose 4B FF in
RIA buffer were added and incubated for 2 h at RT on
an end-over-end shaker. Subsequently, samples were
allowed to settle and the supernatants were discarded in
order to isolate immunocomplexes. Pellets were washed
three times with 200 μL of RIA buffer and once with
200 μL of 0.2 M NaCl in RIA buffer. Finally, pellets were
suspended in 100 μL of 1 % w/v SDS and supernatants
were carefully transferred to vials for scintillation
counting (1 min/tube). Results for each sample were
calculated as Bound% (B%) = 100 × (bound cpm/total
cpm), and expressed as Standard Deviation scores
(SDs) = (B% - Bc%) /SDc, where Bc% is the mean B%
of healthy control sera and SDc its standard deviation.
Samples were considered positive when SDs > 3. This
assay had 66.0 % sensitivity, 97.8 % specificity and 86.43 %
accuracy in the Islet Autoantibody Standardization
Program (IASP) 2015, laboratory 0519.
Blank corrected ELISA with colorimetric detection (bcELISA)
The protocol employed was based on those previously
described [50, 59–61], with minor modifications. Briefly,
polystyrene microplates (Maxisorp, NUNC, Roskilde,
Denmark) were coated ON at 4 °C with 0.50 μg purified
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avidin per well, in coating buffer and washed five times
with PBS. Blocking solution (200 μL/well) was added,
and plates were incubated for 1.5 h. Microplates were
washed three times, and incubated for 4 h at 4 °C with
20.0 ng of TrxIA-2ic-biotin. After washing six times, du-
plicate serum samples diluted 1/10 were added and in-
cubated ON at 4 °C. To measure the non-specific signal,
duplicates of serum samples were incubated in wells
without TrxIA-2ic-biotin. Plates were washed six times,
and bound antibodies were detected with anti-human
IgG-HRP (diluted 1/20,000, 1.5 h at 4 °C). After washing
(five times plus one final wash with PBS), the chromo-
genic substrate was added and plates were incubated in
the dark. The color reaction was stopped with 2 M
H2SO4. The oxidized substrate was measured at 450 nm
with an ELISA plate reader Multiskan EX (Thermo elec-
tron corporation, Vantaa, Finland). Results were calcu-
lated as specific absorbance (As, mean of each sample
minus the mean of their non-specific control), and
expressed as SDs = (As-Ac)/SDc, where Ac is the mean
specific absorbance of healthy control sera and SDc its
standard deviation. The cut-off value of the assay was
set at SDs = 1.6.
Bridge ELISA with chemiluminescent detection (CL-bELISA)
The protocol employed was based on those previously
described [62–65]. White Polystyrene microplates (96 F
Maxisorp white microwell, Thermoscientific, Rockford,
IL, USA) were coated ON at 4 °C with 40.0 ng of puri-
fied TrxIA-2ic per well, washed three times with PBS,
blocked for 1.5 h with 200 μL of blocking solution, and
washed five times. Samples were added in duplicate and
microplates were incubated for 1 h. Plates were then
washed five times and 2.0 ng of TrxIA-2ic -biotin per
well were added (the TrxIA-2ic-biotin employed was syn-
thesized with high rates of biotinylation). After another
1 h incubation, plates were washed five times and bound
TrxIA-2ic -biotin was detected by the addition of
Avidin-HRP diluted 1/500. After 1 h incubation, micro-
plates were washed four times plus one final washing
step with 200 μL of PBS; the chemiluminescent substrate
was added and incubated 1 min in the dark. The chemi-
luminescent reaction was measured in a Victor3 multila-
bel reader (Perkin Elmer, MA, USA). Results were
calculated as specific counts per second (cpss, mean of
each sample minus the mean of blank wells), and
expressed as SDs = (cpss - cpsc) /SDc, where cpsc is the
mean specific cps of healthy control sera and SDc its
standard deviation. Samples were considered positive
when SDs > 2.5.
Statistical analysis
The identity and parallelism between inhibitory dose-
response curves obtained with TrxIA-2ic and TrxIA-
2ic-biotin were analyzed by comparing B/B0min, B/B0max,
Hill slopes and IC50 values by the extra sum-of-squares F
test comparison method. Normal distribution of data was
analyzed by the D’Agostino and Pearson omnibus normal-
ity test. In order to remove outliers from normally distrib-
uted healthy control individuals, the Rout test was
performed. The selection of optimal cut-off values was
based on curves constructed by plotting the calculated
specificity and sensitivity of each protocol vs. the corre-
sponding cut-off values. Statistical significance was evalu-
ated using parametric tests: paired samples Student t test
and unpaired samples Student t test with Welch correc-
tion, or non-parametric tests: Wilcoxon matched-pairs
signed rank test or Mann-Whitney U-test for unpaired
data, when applicable. The correlation between methods
for IA-2A assessment was calculated using the non-
parametric Spearman Rank Correlation. Calculations were
performed using GraphPad Prism version 6.01 for
Windows (GraphPad Software, San Diego California,
USA, www.graphpad.com). A p-value < 0.05 was consid-
ered statistically significant.
Results
IA-2ic expression as a fusion protein with thioredoxin in
E. coli
Competent E. coli GI698 and GI724 strains were trans-
formed with pTrxIA-2ic by electroporation. Protein ex-
pression was induced with Trp in both strains at
different incubation times and temperatures (20 °C and
37 °C for GI698 and GI724, respectively) in order to
achieve optimal conditions for maximal protein produc-
tion. For this analysis, SDS-PAGE and WB for TCL were
carried out with specific protein recognition by poly-
clonal serum to Trx. Figure 2a and b depicts bands com-
patible with TrxIA-2ic theoretical MW (≈55.4 kDa) in
both bacteria strains, whereas such bands are absent in
TCL from non-transformed bacteria under the same ex-
perimental conditions. Maximal protein expression was
detected at 16 h post-induction in TCL from both
strains. In order to select the optimal temperature and
time for induction, bacteria were harvested and lysed as
previously described. The ISF was isolated from both
strains at each induction time, and analyzed by SDS-
PAGE and WB (Fig. 2c and d). Relative protein expres-
sion was compared at 3.0 h after induction, where GI724
strain showed slightly higher values than GI698 as
regards the ≈ 55.4 kDa band from the total protein mass.
Furthermore, almost total loss of protein from ISF in
GI724 strain was observed at 16.0 h after induction.
Purification of TrxIA-2ic
TrxIA-2ic was purified from the ISF of E. coli GI724 lys-
ate after 3 h of induction. The procedure was based on
affinity chromatography in which the Trx portion of
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TrxIA-2ic binds to the resin by its catalytic domain con-
taining vicinal dithiols. Figure 3 depicts SDS-PAGE and
WB of different stages of purification, with high levels of
protein expression revealed (lane 1). One-step purifica-
tion separated most contaminant proteins with little or
no significant loss of TrxIA-2ic relying on the high cap-
acity of the in-house made resin. Based on the quantifi-
cation of the 100 mM 2ME fraction (lanes 6–9) bands,
the purification yielded ≈ 10 mg of 72–77 % pure TrxIA-
2ic/L of culture medium.
Biochemical characterization of TrxIA-2ic
In order to estimate the MW of TrxIA-2ic, an SDS-
PAGE with MW calibrators (phosforilase b, bovine
albumin, ovalbumin, carbonic anhydrase, trypsin in-
hibitor and alpha lactalbumin) was performed. A cali-
bration curve of log MW vs. Rf was constructed (log
MW= -0.9091 × Rf + 4.9932, R
2 = 0.9932) and the un-
known MW of TrxIA-2ic was interpolated. An experi-
mental MW (55,943 Da) compatible to the theoretical
MW (55,358 Da) was obtained (1.1 % error, which is
a satisfactory accuracy for this method) [66]. More-
over, further MW studies were carried with SEC in
order to characterize TrxIA-2ic hydrodynamic behav-
ior and the presence of aggregates (Fig. 4a). These
results revealed the presence of monomeric and dimeric
forms of TrxIA-2ic with the corresponding estimated MW
(61,187 Da and 98,047 Da, respectively). Values were ob-
tained from a calibration curve of log MW vs. Ve (log
MW= -0.1969 × Ve + 6.7149, R
2 = 0.9906). For TrxIA-2ic
identification in eluted fractions, a WB using rabbit poly-
clonal serum to IA-2 was performed, confirming the pres-
ence of the fusion protein at expected monomeric and
dimeric MW. In fact, by subjecting the dimer to reduction
with dithiothreitol, total conversion into the monomer
state was observed (Additional file 2: Figure S2). More-
over, SEC showed a TrxIA-2ic Stokes radius of 33.2 Å for
the monomer peak, which corresponded to a globular
protein of 64,816 Da.
MS analysis of TrxIA-2ic corroborated the agreement
between the chimera MW and the expected value (actual
mass 55,209.008 Da; theoretical mass 55,357.500 Da)
(Additional file 3: Figure S3). The purified fusion protein
was also subjected to proteolytic digestion with trypsin
and chymotrypsin. The peptide profile obtained after di-
gestion was analyzed by Orbitrap mass spectrometry,
achieving 63.25 % total coverage (38.15 % for trypsin and
42.77 % for chymotrypsin) of TrxIA-2ic (498 residues)
(Fig. 4b and c), considering high confidence peptides only;
when low confidence peptides were not filtered, 95.38 %





















































Fig. 2 IA-2ic expression as a fusion protein with Trx in E. coli GI698 and GI724. a and c: SDS-PAGE (12.1 % T 6.0 % C, 1 mm, under reducing
conditions, stained with Coomassie Brilliant Blue R-250), b and d: WB revealed with a rabbit polyclonal serum to thioredoxin as primary antibody.
Samples: Total Cell Lysate for a and b, Intracellular Soluble Fraction for c and d. Lanes 1-4: samples from pTrxIA-2ic transformed E. coli GI698 strain;
lanes 5-8: samples from pTrxIA-2ic transformed E. coli GI724 strain. Lanes 1 and 5: sample before induction (0 h); lanes 2 and 6: sample after 1.5 h
of induction; lanes 3 and 7: sample after 3.0 h of induction; lanes 4 and 8: sample after 16.0 h of induction. Arrows indicate the electrophoretic
mobility of TrxIA-2ic
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coverage of the theoretical composition of the protein was
accounted for.
Immunochemical characterization of TrxIA-2ic
Dose-response curves with 4 IA-2A RBA positive Type 1
diabetic patient sera were performed by RIA, adding
TrxIA-2ic at variable concentrations and using [
35S]IA-2
synthesized in an eukaryotic system (Fig. 5a). All dose-
response curves (log [TrxIA-2ic] vs. B/B0) showed simi-
lar IC50 (ranging from 4.57×10
-9 to 1.30×10-8 M), indi-
cating comparable TrxIA-2ic immunoreactivity with sera.
The immunochemical ability of TrxIA-2ic to compete
with [35S]IA-2 was assessed qualitatively by incubating
30 Type 1 diabetic patients sera in the presence of
190 nM TrxIA-2ic (Fig. 5b). All tested sera were IA-
2A positive with SDs of 17.00 ± 8.29 (mean ± SD), me-
dian 14.90, range 4.24 to 35.09 and cut-off value for
positivity SDs = 3.0. A significant difference between
sera from Type 1 diabetic patients and healthy con-
trol individuals was observed (Unpaired samples
Student t test with Welch correction, p <0.0001). All
type 1 diabetic patient sera became virtually negative
under antigen excess (comparable to healthy control
individuals SDs): median SDs changed from 14.90 to -0.16
(range -1.31 to 4.73) with cold TrxIA-2ic excess (Wilcoxon
test for paired samples, p <0.0001).
Competitive quantitative and qualitative assays were
also performed for TrxIA-2ic-biotin in order to evaluate
any distortion in epitopes caused by biotynilation. The
immunochemical identities between TrxIA-2ic and
TrxIA-2ic-biotin were analyzed and expressed in terms
of parallelism. As seen in Fig. 5c, when using a pool of
IA-2A+ human sera, parallelism and identity between
curves was achieved (one curve adequately fits all data,
alpha = 0.05, R2 = 0.9492). Similar results were obtained
for TrxIA-2ic biotinylated under conditions of high bio-
tin concentrations (Additional file 4: Figure S4). The in-
hibition assay for TrxIA-2ic-biotin was performed by
incubating 30 Type 1 diabetic patient sera in the
presence of 140 nM TrxIA-2ic-biotin (Fig. 5d). All tested
sera were IA-2A positive with an SDs of 14.16 ± 4.17
(mean ± SD), median 13.53, range 7.68 to 22.27 and a
cut-off value for positivity SDs = 3.0. It can be observed
that sera from Type 1 diabetic patients differed signifi-
cantly from healthy control samples (Unpaired t test
with Welch correction, p <0.0001). All patient sera be-
came virtually negative (comparable to healthy control
individuals) under antigen excess: mean SDs changed
from 14.16 to 0.01 (median -0.67, range -2.52 to 4.13)
with cold TrxIA-2ic-biotin excess (Student t test for
paired samples, p <0.0001).
Storage and stability studies
Displacement curves were performed over time (120 d)
using a pool of 5 sera from IA-2A positive Type 1 dia-
betic patients and the tracer [35S]IA-2 in competition
with cold TrxIA-2ic under different storage conditions.
Inhibition dose response curves (log [TrxIA-2ic] vs. B/B0)
were drawn for each condition and the IC50 value was de-
termined and plotted against time (Fig. 5e). As it can be
observed, the IC50 values remained relatively constant
over time for the storage condition of -20 °C in 50 % v/v
glycerol, 50 mM 2ME lysis buffer, indicating that the im-
munoreactivity was maintained throughout the evaluation
period. Contrarily, the storage condition at -20 °C in
100 mM 2ME lysis buffer caused a gradual increase in the
IC50 value until t = 120 d, when the dose-response curve
could no longer be properly fitted.
TrxIA-2ic application in immunoassays for IA-2A
assessment
Forty eight sera from children and adolescents with
T1DM were tested in parallel by RBA, bcELISA and
CL-bELISA for IA-2A detection. The specificity was
calculated as 100 % minus the percentage of false
positives, using control individuals (n = 37, 23 or 39
for RBA, bcELISA and CL-bELISA, respectively). In
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Fig. 3 Purification of TrxIA-2icby affinity chromatography. Analysis of
TrxIA-2ic fractions at different stages of purification by a: SDS-PAGE
(10.0 % T 6.0 % C, 1 mm thickness, under reducing conditions,
stained with Coomassie Brilliant Blue R-250) and b: WB revealed with
a rabbit polyclonal serum to thioredoxin as primary antibody. In A
and B, lane 1 corresponds to total ISF from transformed E. coli GI724,
lane 2: unbound material or pass through of the column, lanes 3-5:
washes with increasing 2ME concentrations (0, 1 and 5 mM), lanes
6-9: 100 mM consecutive eluates of purified TrxIA-2ic. Arrows indicate
the electrophoretic mobility of TrxIA-2ic
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control individuals, outlier removal was needed (Rout
test, Q = 1 %); however, these outliers were included
in all plots and also for specificity calculations, as
they were considered false positives. When analyzed
by RBA, 42 sera were positive (87.5 %), while 6 were
negative (12.5 %). A median SDs of 13.74 was ob-
tained, ranging from -0.84 to 57.08; cut-off value for
positivity SDs = 3.0 (Fig. 6a and Table 1). With this
analysis, a specificity of 97.3 % was obtained and
healthy control individuals differed significantly from
T1DM patients (p < 0.0001).
Results were obtained from healthy control and newly
diagnosed T1DM patient sera (n = 48).
By bcELISA, a total of 19 sera out of the 48 T1DM pa-
tients analyzed were positive (39.6 % sensitivity), with
SDs ranging from -2.76 to 4.85, and an SDs = 1.01 ± 1.55
(mean ± SD), median 1.05 and cut-off value for positivity
SDs = 1.6. Out of the 42 IA-2A positive sera by RBA, 17
scored positive by bcELISA, whereas 29 patients were
negative (Fig. 6b). These results indicated that bcELISA
had an analytical sensitivity of 40.5 % for this sera collec-
tion (percentage of patients RBA positive that were posi-
tive by bcELISA) and 95.7 % specificity when analysis of
healthy control sera was performed (Table 1). It is note-
worthy that the RBA failed to render positive reactions
in 2 patients that were indeed detected by the bcELISA.
Populations significantly differed for median antibody
levels (p = 0.0032).
Out of the 48 patient sera, 28 scored positive for
IA-2A by CL-bELISA (58.3 % sensitivity), whereas 20
patients were negative (41.7 %) (Fig. 6c). Twenty five
IA-2A positive sera by RBA scored positive when
evaluated by CL-bELISA, showing an analytical sensi-
tivity of 59.5 %, SDs ranging from -0.71 to 111.20
and a median SDs = 3.46 (Table 1). Healthy control
sera (n = 39) resulted in 94.9 % specificity and showed
two different statistical populations that needed outliers
removal by the Rout test (Q = 1 %). Remaining results
were normally distributed. In order to achieve maximum
analytical sensitivity for this protocol, SDs > 2.5 was
chosen as the cut-off value. As seen for bcELISA, CL-
bELISA detected 3 positive sera that the RBA could
not, one of which was positive for bcELISA as well.
Populations significantly differed for median antibody
levels (p < 0.0001).
The Venn’s diagram (Fig. 6d) depicts the integrated
results of RBA, bcELISA, and CL-bELISA. As shown
on this figure, 12 out of 48 sera were positive by
RBA, bcELISA, and CL-bELISA, while 2 were negative




Fig. 4 Biochemical characterization of TrxIA-2ic. a: Size Exclusion Chromatography of affinity-purified TrxIA-2ic (solid line) and molecular weight
globular calibrators (dotted line) performed on a Superdex 75 column (insert: calibration curve). The detector was set at 280 nm. From left to right,
calibrator peaks correspond to human gamma-globulin (158 kDa), ovalbumin (44 kDa), horse myoglobin (17 kDa) and B12 vitamin (1.35 kDa). Arrows
indicated peaks from monomeric (Ve = 9.793 mL) and dimeric TrxIA-2ic (Ve = 8.753 mL). b: TrxIA-2ic sequence. Underlined and highlighted in bold are
those fragments identified by Orbitrap Mass Spectrometry considering high confidence peptides. c: TrxIA-2ic N-terminal Trx fraction, the linker peptide
and the IA-2ic fragment in the C-terminal of the construction are detailed in the scheme above, and the corresponding peptide fragments identified
by Orbitrap Mass Spectrometry are highlighted in the diagram below. JM: Juxtamembrane





Fig. 5 Immunochemical characterization and storage study. a: Dose-response curves for 4 IA-2A RBA positive Type 1 diabetic patient sera incubated
with different concentrations of TrxIA-2ic. Each curve includes best-fit values from the log (inhibitor) vs. response - Variable slope (four parameters)
equation: correlation coefficient data (R2), IC50 values and an approximation to the affinity constant of IA-2A (Ka) calculated as the inverse of IC50. b:
Inhibition capacity of TrxIA-2ic assessed in 30 IA-2A positive type 1 diabetic patient sera in the absence (left) or presence (right) of TrxIA-2ic. Twenty
healthy control sera were used in order to set a cut-off value. c: Dose-response curves for a pool of 3 IA-2A RBA positive Type 1 diabetic
patient sera for different concentrations of TrxIA-2ic (open circle, solid line) and TrxIA-2ic-biotin (closed circle, dotted line). d: Inhibition capacity of TrxIA-2ic-
biotin assessed in 30 IA-2A positive Type 1 diabetic patient sera in the absence (left) or presence (right) of TrxIA-2ic-biotin. Twenty healthy control sera
were used in order to set a cut-off value. Binding is expressed as SDs, and the dotted lines represent the cut-off value. e: IC50 vs. storage time for TrxIA-
2ic stored at -20 °C in 100 mM 2ME lysis buffer (solid line) and -20 °C in 50 % glycerol, 50 mM 2ME lysis buffer (dotted line). These assays were performed
by standard RIA protocols, as described in Methods.
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RBA and bcELISA, while 13 were only positive by both
RBA and CL-bELISA. Moreover, bcELISA and CL-bELISA
were able to detect 4 patients that were found negative by
RBA (1 serum found positive only by bcELISA, 2 sera posi-
tive only by CL-bELISA and 1 sera positive by both
methods). The latter sera were not considered false posi-
tives since these samples had been obtained from newly
diagnosed patients with T1DM. CL-bELISA was able to
detect 15 IA-2A positive sera that bcELISA was not;
whereas bcELISA detected 6 patients as IA-2A positive
that CL-bELISA did not. The Spearman correlation coeffi-
cient (r = 0.6650 for bcELISA and CL-bELISA) and p value
(p = 0.0005) showed that the pairing was significantly ef-
fective and there was an acceptable concordance between
both methods; however, no significant correlation between
antibody levels by RBA and either solid phase tests was
found.
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Fig. 6 Immunoassays for IA-2A assessment in healthy control and Type 1 diabetic patient sera. The results, expressed as SDs, were obtained by
RBA (a), bcELISA (b) and CL-bELISA (c). The cut-off value for each assay is indicated by a dotted line and medians for each population are indicated
by a dashed line. d: Venn’s diagrams for integrated IA-2A results for children and adolescents with newly diagnosed T1DM, obtained by RBA, bcELISA,
and CL-bELISA
Table 1 Analytical parameters from RBA, bcELISA and CL-bELISA
Assay RBA bcELISA CL-bELISA
Healthy control individuals (n) 37 23 39
Type 1 diabetic patients (n) 48
Median (SDs) 13.74 1.05 3.46
Range (SDs) (-0.84)-57.08 (-2.76)-4.85 (-0.71)-111.20
Sensitivitya (%) 87.5 39.6 58.3
Specificityb 97.9 95.7 94.9
Analytical Sensitivityc (%) - 40.5 59.5
aPercentage of IA-2A positive patients from the total population studied
b100 % minus the percentage of false positives
cPercentage of patients RBA positive that were positive by each method
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Discussion
Although radiometric methods have an excellent per-
formance in the diagnosis of DM, the use of radioactive
isotopes is falling out of use because of their multiple
disadvantages (high costs, waste management difficul-
ties, low applicability in laboratories, centralization of
determinations, etc.). Therefore, the development of al-
ternative methods of acceptable performance, greater
simplicity, lower cost and more applicability in low com-
plexity laboratories are needed. The methods most
widely used include solid phase immunoassays which re-
quire large amounts of antigen for their development
and routine application. Our laboratory has previously
attempted to produce recombinant IA-2ic in order to
implement ELISA-like tests [50]; however, due to the in-
stability of the product (Poskus E, personal communica-
tion) the RBA for IA-2A remains the method of choice
for routine analysis in Argentina.
In this work, an alternative approach for IA-2ic expres-
sion was developed. The methodology presented herein
involved the production of soluble cytoplasmic IA-2ic by
means of the solubilising effect of Trx [49], which is
a phenomenon already observed for other proteins
[67–70]. The use of the Trx fusion partner increases
the chance of correct folding, which is critical for
binding of autoantibodies from patients with T1DM.
The expression of TrxIA-2ic was accomplished in E. coli
GI698 and GI724 strains (Fig. 2). High production levels
of the C-terminal fusions to thioredoxin were obtained
through the use of pTrxFus vector carrying pL, which is a
strong bacteriophage λ promoter. As advised, collection of
samples at different timepoints during the course of the
induction period was carried out in order to evaluate
variations in protein solubility, stability and concentration
[49, 71]. The lysis of harvested bacteria was performed
and the ISF evaluation was carried out (Fig. 2). Even
though a substantial expression of TrxIA-2ic was observed
in both strains, GI724 showed a slightly higher protein ex-
pression under shorter induction periods than GI698. The
expression of soluble TrxIA-2ic became minimal under
ON incubations in the GI724 strain, which was expected
for large induction times under higher temperatures. It
can be speculated that under such conditions, TrxIA-2ic
became unstable due to the excessive synthesis and im-
proper folding, a phenomenon that led to insolubilisation
and product accumulation in the form of inclusion bodies
(IB). This observation was corroborated by SDS-PAGE
and WB of isolated IB (Additional file 5: Figure S5). On
the other hand, the expression in GI698 strain rendered
good levels of protein, with a maximum at 16 h of
induction, and minimal visualization of degradation
by-products, probably due to low activity of proteases
at 20 °C. Although GI698 strain should not be com-
pletely ruled out as a valuable source of TrxIA-2ic,
shorter induction times are preferred for scaling up
procedures. Taking into account these results, the ex-
pression in GI724 strain employing a 3 h induction
time, was selected as optimal condition for TrxIA-2ic
production in any low-medium complexity laboratory
and was therefore used for further studies.
The purification of TrxIA-2ic from the ISF was accom-
plished by a single step of affinity chromatography using
an agarose-based matrix with arsenic residues. This
chemical ligand binds selectively to vicinal dithiols, such
as the ones present in the catalytic site of Trx (binding
motif Cys-Gly-Pro-Cys). The levels of soluble protein ex-
pression obtained in E.coli GI724 were higher than those
previously reported in the literature for prokaryotic sys-
tems [72, 73]. High purity levels were achieved, even
higher than those reported in the results section (72–
77 %), which does not include the contribution of
TrxIA-2ic dimer. Furthermore, these unique properties
of the fusion partner allowed us to establish a general
platform for expression and purification of soluble Trx
fusion proteins, such as TrxGAD and TrxPI [68, 70],
along with TrxIA-2ic, applicable to the laboratory diag-
nosis of autoimmune DM. The amount of protein ob-
tained with this methodology was suitable for the
development of solid phase IA-2A immunoassays; in
fact, the result of a standard purification protocol may
allow passive adsorption of more than 500 96-well poly-
styrene microplates. Taking into account these results,
the affinity purified TrxIA-2ic from ISF was further
characterized.
The first quality control step was to verify if TrxIA-2ic
had the theoretical expected MW. The analysis of the
purified protein by SDS-PAGE, SEC and MS rendered
results that coincided, within the experimental error,
with the theoretical MW values calculated from the se-
quence. Furthermore, we observed that under native
conditions, both a monomeric form and aggregates of a
dimer-like conformation would coexist when solubilised.
The SDS-PAGE analysis employing dithiothreitol dem-
onstrated that these dimers were bound by covalent
bonds, specifically disulfide bonds (Additional file 2:
Figure S2). According to literature [74], the cysteine resi-
dues were unlikely to form disulfide bonds, contributing
little to the three dimensional structure of the protein.
Probably, disulfide bridges are formed later due to the
action of reactive oxygen species during storage or the
IA-2ic PTP and juxtamembrane domains tendency to
dimerize [75–77], leading to polymerization. This in
vitro observation could be a resemblance of the in vivo
regulation of many receptor-type PTPs. Furthermore,
the oxidation of the core cysteine (C909) to cysteic acid
would block access of antibodies, which turns storage
buffer a critical aspect in the stability of IA-2ic [78]. For
this reason, we decided to maintain the 2ME reducing
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conditions after purification. Regarding the determin-
ation of the Stokes radius of the protein, since TrxIA-2ic
is a 55,358 Da protein, the hydrodynamic behavior was
compatible with a properly folded monomer that devi-
ates moderately from an ideal sphere (different elution
behaviour between the standard and the unknown pro-
teins) [66]. Upon performing MS analysis after proteo-
lytic digestion, sequence coverage of 63.25 % was
achieved over the 498 residues constituting the TrxIA-
2ic, which is a percentage suitable to accomplish the
autoantigen identification. Taking into account the bio-
chemical characterization of the entire protein, we have
expressed genuine human IA-2ic as a fusion protein with
Trx.
Immunochemical studies of TrxIA-2ic allowed us to
demonstrate that the protein is able to displace the bind-
ing of radiolabeled eukaryotic IA-2ic from IA-2A, thus
confirming the integrity of conformational epitopes in
the recombinant antigen, which is a critical requirement
to IA-2A recognition. It is noteworthy that the approxi-
mate Ka values obtained for 4 sera were in the order of
108 M-1, which correlates with literature data (107–
1011 M-1) [79]. Since the calculated Ka for IA-2A were,
within the limits of experimental error, the same for
TrxIA-2ic and these previously published data for IA-2ic
from E. coli, it can be speculated that the epitopes as
well as the overall protein conformation are not affected
during prokaryotic expression and Trx fusion. Further-
more, with a larger number of IA-2A positive patient
sera, we demonstrated that they were able to recognize
recombinant TrxIA-2ic, displacing the radioactively la-
belled eukaryotic antigen. Considering that most sera
from type 1 diabetic patients only target conformational
discontinuous epitopes of IA-2ic [29], this result rein-
forces the hypothesis of a correct folding of epitopes in
the IA-2ic portion, probably due to the presence of ener-
getically or kinetically favourable conditions.
Even though an EK site was included in the plasmid, a
further enzymatic removal of the Trx portion from the
fusion protein to avoid cross reaction phenomena was
not necessary since we have previously demonstrated
that healthy control and diabetic sera do not react with
bacterial Trx [53]. Therefore, we have decided to use the
entire fusion protein for the development of immunoas-
says since Trx did not interfere with IA-2A recognition,
it helped in proper protein folding and stability, and
even simplified purification. Furthermore, the amino
group of the N-terminal portion of Trx could be useful
to improve the orientation of IA-2ic on surfaces with free
carboxyl residues by covalent bonds, such as those
required in Surface Plasmon Resonance CM5 sensor
chips for thermodynamic and kinetic studies of autoanti-
bodies, and in polystyrene microspheres for flow cytom-
etry [53, 80].
In order to increase the possibilities for immunoassay
development, TrxIA-2ic was biotinylated. When the im-
munochemical behavior of TrxIA-2ic-biotin was studied,
the dose-response curves generated by RIA showed
identity between TrxIA-2ic and its biotinylated counter-
part, according to the general principles of immuno-
chemical cross reactivity [81]. Furthermore, competitive
qualitative assays showed that all patient sera became
virtually negative under TrxIA-2ic-biotin excess. All
these results indicate that the recognition by IA-2A of
both TrxIA-2ic and the biotinylated protein was practic-
ally the same; therefore, it could be deduced that the bi-
otinylation did not alter critical epitopes for interaction
with IA-2A.
Stability studies in the storage condition at -20 °C in
100 mM 2ME lysis buffer indicated that as TrxIA-2ic
storage time proceeds, the displacing concentration re-
quired for a response half between B/B0min and B/B0max
(IC50) was increasing to the point of no longer being
recognized by IA-2A. However, TrxIA-2ic immunoreac-
tivity was maintained throughout the evaluation period
when the fusion protein was kept at -20 °C in 50 % v/v
glycerol, 50 mM 2ME lysis buffer. For this reason, the
latter storage condition was selected, which ensured im-
munochemical quality of the recombinant antigen for at
least four months, being applicable to routine immuno-
assays for the detection of IA-2A. This finding is one of
the most interesting properties of the protein under
study, as previous attempts in our laboratory failed to
obtain IA-2ic with sufficient stability to yield immunoas-
says for routine applications, as most of the soluble pro-
tein precipitated within 24 h.
Since TrxIA-2ic could be expressed in a simple pro-
karyotic system with high yields, purity and stability, and
it was properly identified and immunoreactive against
IA-2A positive patient sera, we proceeded to apply this
protein in non-radiometric methods for IA-2A detec-
tion. To start with, a population of 48 children and ado-
lescents with newly diagnosed T1DM were subjected to
IA-2A assessment by the reference method RBA, which
shows the best sensitivity and specificity parameters in
international quality controls (such as the Diabetes
Autoantibody Standardization Program –DASP- and
IASP). As previously described [64, 82], it is currently
accepted that RBA alone is not enough to rule out the
existence of autoimmunity in childhood diabetic pa-
tients; therefore, the performance of simultaneous deter-
minations of all major markers (IAA, GADA, IA-2A and
ZnT8A) is recommended. In this work, we managed to
develop two methods capable of detecting IA-2A in
some sera that RBA could not, probably due to differ-
ences in the principles of detection [83–85]. It has also
been demonstrated that fluid phase radiometric assays
may underestimate the IA-2A titers due to the formation
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of insoluble immune complexes which do not bind to
Protein A-Sepharose, a phenomenon that would not
occur in solid phase immunoassays [86].
The first alternative method, bcELISA, included the de-
velopment of a solid phase immunoassay, based on a
standard design for detection of antibodies, similar to an
indirect ELISA, characterized by the immobilization of the
biotinylated antigen to the microplate via an avidin bridge
[50, 61]. This design emerged as a viable option for solving
the possible denaturation of the protein when adsorbed
onto the plastic surface of the microplate [87], which
would be deleterious for IA-2A binding mainly because
they recognize discontinuous epitopes. Unfortunately, the
performance parameters showed a narrow dynamic range
and high signals with healthy control sera, with the conse-
quent low sensitivity (39.6 %) and relative sensitivity
(40.5 %) unsuitable for routine application. Another draw-
back of this assay is the requirement of a large sample vol-
ume, which makes it impractical when children and
juvenile patients must be assessed. However, these per-
formance values do not differ much from previous data
corresponding to the same design for IA-2A [50, 59, 60]
or GADA [61]. The poor performance could not be
attributed to alterations in critical epitopes for recognition
by IA-2A since it was shown that TrxIA-2ic-biotin
exhibited immunoreactivity comparable to TrxIA-2ic. This
phenomenon could be attributed to differences in the
principles of antigen:antibody interaction (fluid phase vs.
solid phase) and detection (radiometric vs. colorimetric).
In order to improve the performance in IA-2A assess-
ment, we proceeded to the optimization of CL-bELISA,
the first described test for the determination of IA-2A
with chemiluminescent detection. While this detection
shows increased sensitivity, it can lead to higher non-
specific signal as well. For this reason we decided to de-
velop an immunoassay variant with high specificity. One
way to reduce the background signal is to use the la-
belled specific antigen to detect bound antibody instead
of the detection of total bound IgG with labelled xeno-
geneic anti-immunoglobulin antibody, which decreases
the signal-to-background ratio [65]. Previous data ob-
tained by our research group have shown that this de-
sign has acceptable performance values for the clinical
application in routinely GADA determination in conven-
tional ELISA or flow cytometry-based immunoassays
[64, 82]. The design is based on the immobilization of
the antigen to the solid phase, the incubation with the
specific autoantibody (crosslinking molecule) and a fluid
phase interaction with the biotinylated antigen via the
available paratope. For detection of IA-2A, we demon-
strated that it presented a wide dynamic range, even
higher than that described for the reference method.
The parameters of sensitivity (58.3 %), relative sensitivity
(59.5 %) and specificity (94.9 %), although lower than
those for RBA, are more than acceptable for use as a
first line screening method for assessing humoral
markers. It is difficult to compare the performance of
this assay with those of previous studies where IA-2A is
detected because in those studies different antigens were
used, as well as different patient populations and healthy
control individuals (with variables such as number, eth-
nicity and, possibly, sample matrix) [62, 63, 74–77]. The
lower sensitivity showed by CL-bELISA, in comparison
with RBA, could be a consequence of partial denatur-
ation of TrxIA-2ic when adsorbed onto the surface of
polystyrene microplates. Concerning the epitopes recog-
nized by IA-2A, it was previously found that these auto-
antibodies mostly recognize the C-terminal domain of
IA-2 [33]. Thus, it is not surprising that the Trx moiety,
which is an N-terminal extension of Trx-IA-2ic, did not
adversely affect the sensitivity of the ELISAs reported
here. The lack of correlation between solid-phase and
liquid-phase assays has been previously reported and
discussed [84, 88–90]. In this sense, different thermo-
dynamic principles apply to ELISA and RBA, since in
the latter antigen–antibody reaction occurs in the liquid
phase, in high dilution and near the equilibrium; mean-
while in both ELISA protocols the interaction occurs in
solid phase, where the amount of immunocomplexes is
highly dependent on antibodies concentration. In fact, in
T1DM, autoantibodies concentration is really low (in the
order of 10-12 M), turning their detection into an analyt-
ical challenge using solid phase assays, especially for sen-
sitivity limitations. Then, as expected, there was a low
correlation between the results obtained by both ELISA
protocols and RBA. This protocol also used a lower vol-
ume of sera than bcELISA, but still higher than that used
in RBA (2.5 μL of undiluted sera). Concerning healthy
control individuals, the presence of possible false posi-
tive may be due to a matrix effect caused by samples
from patients who did not have the proper fasting as
diabetic patients did. As mentioned above, the presence
of anti-Trx crossreactivity in healthy control sera could
be ruled out [53]. When a comparison was made with
bcELISA, CL-bELISA had higher values for the above
mentioned analytical parameters. In addition, the differ-
ences in dynamic range between methods can be ex-
plained, at least partially, by higher sensitivity with
chemiluminiscent detection and increased signal-to-
background ratio in immunoassay design. As regards dif-
ferential detection of immunoglobulin isotypes, while CL-
bELISA can potentially detect any, other immunoassays
have limitations for binding specificity to the antibody
conjugated to peroxidase (bcELISA) or protein A (RBA).
In order to better characterize the performance of CL-
bELISA, we increased the number of type 1 diabetic pa-
tients (n = 60) and healthy controls (n = 115) samples
already tested (Additional file 6: Figure S6). As a result, a
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sensitivity of 56.7 %, an analytical sensitivity of 59.6 % and
a specificity of 97.4 % were obtained. It is noteworthy that
in the DASP and the IASP the number of samples that are
received to evaluate the analytical performance of different
immunoassays is similar to the number used in this work.
Employing a higher number of samples, the sensitivity
values remained fairly the same; however a slightly in-
creased in the specificity of the assay was observed since
the percentage of detected outliers decreased in a more
representative population. This data reinforces the applic-
ability of CL-bELISA in IA-2A routine determination.
Conclusion
The findings of this study can be summarized in the fol-
lowing statements: i) the recombinant vector pTrxIA-2ic
was designed, synthesized and quality-controlled, ii) sol-
uble human IA-2ic was expressed as a properly folded
thioredoxin fusion protein in E. coli, iii) higher levels of
TrxIA-2ic expression were obtained after 3 h of induction
on GI724 strain, iv) highly pure TrxIA-2ic was recovered
from the intracellular soluble fraction after a single step
purification by affinity chromatography, v) the MW of
TrxIA-2ic could be estimated by SDS-PAGE, SEC and
MS, vi) the presence of TrxIA-2ic soluble monomers and
covalent-mediated dimers was determined under native
conditions, vii) TrxIA-2ic was properly identified by WB
and MS, viii) excellent immunochemical behavior of prop-
erly folded full TrxIA-2ic was validated by inhibition or
displacement of [35S]IA-2 binding from IA-2A, ix) great
stability over time was found under proper storage condi-
tions and x) low cost and environmentally harmless non-
radiometric methods for IA-2A assessment were devel-
oped, which are accessible to many laboratories.
Furthermore, methods for IA-2A detection by flow cy-
tometry based on the use of polystyrene microspheres,
with the potential simultaneous determination of the
main humoral markers of autoimmune DM are cur-
rently being developed in our laboratory [64], since
multiplex testing will facilitate high-throughput screen-
ing of T1DM in the general population [91]. It is clear
that better tests based on pure antigen preparations will
allow better screening of DM risk, characterizing the
course of the disease and the distinction between DM of
immune origin and that of metabolic cause.
Additional files
Additional file 1: Figure S1. Affinity purification of thioredoxin fusion
proteins with an agarose-based support covalently modified with
phenylarsine oxide. Thioredoxin fusion proteins, containing vicinal
dithiols in their active site (CysGlyProCys region), reversibly bind the
hydrophobic trivalent arsenic functional site and are eluted using
2-mercaptoethanol (2ME). Affi-Gel 10 (Bio-Rad Laboratories Inc.) was
used as the agarose-based support. (PDF 170 kb)
Additional file 2: Figure S2. TrxIA-2ic identification by western blot in
eluted fractions from size exclusion chromatography and dithiothreitol
reduction analysis. WB was revealed with a rabbit polyclonal serum to IA-
2ic as primary antibody. A: Identification of monomeric and dimeric forms
of TrxIA-2ic. Lane 1: affinity purified TrxIA-2icfrom E. coli GI724 strain; lane
2: eluted fraction at Ve = 8.75 mL, corresponding to dimeric TrxIA-2ic; lane
3: eluted fraction at Ve = 9.79 mL, corresponding to monomeric TrxIA-2ic;
B: Conversion to TrxIA-2ic monomeric form under dithiothreitol reduction.
Lane 1: TrxIA-2ic under denaturalizing and reducing conditions (8 M urea
and 100 mM dithiothreitol). Arrows indicate the electrophoretic mobility
of monomeric TrxIA‑2ic. (PDF 186 kb)
Additional file 3: Figure S3. Mass spectrometric analysis of TrxIA-2ic. A
molecular weight of 55,209.008 Da indicates the major peak consistent
with the expected molecular mass of TrxIA-2ic. Samples were analyzed on
a Bruker Microflex MALDI-TOF device. (PDF 204 kb)
Additional file 4: Figure S4. Competitive quantitative assay for TrxIA-2ic
and TrxIA-2ic-biotin synthesized with high rates of biotinylation. Dose-
response curves for a pool of 3 IA-2A RBA positive Type 1 diabetic patient
sera for different concentrations of TrxIA-2ic (open circle, solid line) and
TrxIA-2ic-biotin (closed circle, dotted line). Parallelism and identity between
curves was achieved (one curve adequately fits all data, alpha = 0.05,
R2 = 0.9653). (PDF 111 kb)
Additional file 5: Figure S5. IA-2ic expression as a fusion protein with
Trx in E. coli GI724 inclusion bodies. A: SDS-PAGE (12.1 % T 6.0 % C,
1 mm, under reducing conditions, stained with Coomassie Brilliant Blue
R-250), B: WB revealed with a rabbit polyclonal serum to thioredoxin as
primary antibody. Lanes 1–4: samples from pTrxIA-2ic transformed E. coli
GI724 strain. Lane 1: sample before induction (0 h); lane 2: sample after
1.5 h of induction; lane 3: sample after 3.0 h of induction; lane 4: sample
after 16.0 h of induction. Arrows indicate the electrophoretic mobility of
TrxIA-2ic. (PDF 254 kb)
Additional file 6: Figure S6. CL-bELISA for IA-2A assessment in 115
healthy control and 60 Type 1 diabetic patient sera. The results are
expressed as SDs, the cut-off value (2.5) is indicated by a dotted line and
medians for each population are indicated by a dashed line. Out of the
60 patient sera, 34 scored positive (56.7 % sensitivity), whereas 26 patients
were negative. Thirty one IA-2A positive sera by RBA scored positive
when evaluated by CL-bELISA, showing an analytical sensitivity of 59.6 %,
SDs ranging from -1.010 to 111.20 and a median SDs = 3.18. Healthy
control sera (n = 115) results showed a specificity of 97.4 %. (PDF 237 kb)
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